PROBIOTICS TO IMPROVE GUT MICROBIOTA

摘要

THE USE OF BIFIDOBACTERIUM LACTIS CNCM I-3446 IN THE MANUFACTURE OF A MEDICAMENT OR THERAPEUTIC NUTRITIONAL COMPOSITION FOR PROMOTING THE DEVELOPMENT OF AN EARLY BIFIDOGENIC INTESTINAL MICROBIOTA IN INFANTS DELIVERED BY CAESAREAN SECTION IS DISCLOSED. FIG. 2